{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:48:27Z","timestamp":1792698507711,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.1001\/jamaneurol.2019.2764","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T20:54:40Z","timestamp":1567544080000},"page":"1457","source":"Crossref","is-referenced-by-count":310,"title":["Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis"],"prefix":"10.1001","volume":"76","author":[{"given":"Jos\u00e9 M.","family":"Ferro","sequence":"first","affiliation":[{"name":"Department of Neurosciences and Mental Health, Servi\u00e7o de Neurologia, Hospital Santa Maria\/Centro Hospitalar Lisboa Norte, Lisbon, Portugal"},{"name":"Instituto de Medicina Molecular and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Coutinho","sequence":"additional","affiliation":[{"name":"Department of Neurology, Academic Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dentali","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Insubria University, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences and Physical Education, Kazimierz Pulaski University of Technology and Humanities Radom, Warsaw, Poland"},{"name":"Interventional Stroke and Cerebrovascular Disease Treatment Center, Institute of Psychiatry and Neurology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Alasheev","sequence":"additional","affiliation":[{"name":"Sverdlovsk Regional Clinical Hospital No 1, Yekaterinburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Canh\u00e3o","sequence":"additional","affiliation":[{"name":"Department of Neurosciences and Mental Health, Servi\u00e7o de Neurologia, Hospital Santa Maria\/Centro Hospitalar Lisboa Norte, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Karpov","sequence":"additional","affiliation":[{"name":"Neurology Department, Regional State Budget Healthcare, City Hospital No. 5, Barnaul, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Nagel","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Posthuma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Academic Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M\u00e1rio","family":"Roriz","sequence":"additional","affiliation":[{"name":"Neurology Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Caria","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Fr\u00e4ssdorf","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Huisman","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim BV, Alkmaar, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Reilly","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the RE-SPECT CVT Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"noi190070r1","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1161\/STROKEAHA.112.671453","article-title":"The incidence of cerebral venous thrombosis: a cross-sectional study.","volume":"43","author":"Coutinho","year":"2012","journal-title":"Stroke"},{"issue":"9","key":"noi190070r2","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1161\/STROKEAHA.116.013617","article-title":"Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study.","volume":"47","author":"Devasagayam","year":"2016","journal-title":"Stroke"},{"issue":"2","key":"noi190070r3","first-page":"117","article-title":"Cerebral vein and dural sinus thrombosis in adults in Isfahan, Iran: frequency and seasonal variation.","volume":"117","author":"Janghorbani","year":"2008","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"noi190070r4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/01.STR.0000117571.76197.26","article-title":"Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).","volume":"35","author":"Ferro","year":"2004","journal-title":"Stroke"},{"issue":"9","key":"noi190070r5","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1161\/STROKEAHA.110.581223","article-title":"Venous thromboembolic events after cerebral vein thrombosis.","volume":"41","author":"Miranda","year":"2010","journal-title":"Stroke"},{"issue":"25","key":"noi190070r6","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1161\/CIRCULATIONAHA.109.927046","article-title":"Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis.","volume":"121","author":"Martinelli","year":"2010","journal-title":"Circulation"},{"issue":"4","key":"noi190070r7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1161\/STR.0b013e31820a8364","article-title":"Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"42","author":"Saposnik","year":"2011","journal-title":"Stroke"},{"issue":"10","key":"noi190070r8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/ene.2017.24.issue-10","article-title":"European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis\u2014endorsed by the European Academy of Neurology.","volume":"24","author":"Ferro","year":"2017","journal-title":"Eur J Neurol"},{"key":"noi190070r9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.vph.2018.04.001","article-title":"State of play and future direction with NOACs: an expert consensus.","volume":"106","author":"Cohen","year":"2018","journal-title":"Vascul Pharmacol"},{"issue":"12","key":"noi190070r10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"noi190070r11","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism.","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"noi190070r12","doi-asserted-by":"publisher","first-page":"915.e11","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.02.004","article-title":"Use of direct thrombin inhibitor for treatment of cerebral venous thrombosis.","volume":"21","author":"Hon","year":"2012","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"8","key":"noi190070r13","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1161\/STROKEAHA.114.006167","article-title":"Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.","volume":"45","author":"Geisb\u00fcsch","year":"2014","journal-title":"Stroke"},{"issue":"7","key":"noi190070r14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/ijs.12462","article-title":"Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients.","volume":"10","author":"Mendon\u00e7a","year":"2015","journal-title":"Int J Stroke"},{"issue":"Suppl A100","key":"noi190070r15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ijs.12592","article-title":"Rivaroxaban for the treatment of cerebral venous thrombosis.","volume":"10","author":"Mutgi","year":"2015","journal-title":"Int J Stroke"},{"key":"noi190070r16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jns.2017.09.007","article-title":"Apixaban for the treatment of cerebral venous thrombosis: a case series.","volume":"381","author":"Rao","year":"2017","journal-title":"J Neurol Sci"},{"issue":"7","key":"noi190070r17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1177\/1747493018778125","article-title":"Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis.","volume":"13","author":"Ferro","year":"2018","journal-title":"Int J Stroke"},{"issue":"4","key":"noi190070r18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jth.2005.3.issue-4","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"10","key":"noi190070r19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/j.1468-1331.2010.03011.x","article-title":"EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients.","volume":"17","author":"Einh\u00e4upl","year":"2010","journal-title":"Eur J Neurol"},{"issue":"5","key":"noi190070r20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/003693305700200504","article-title":"Cerebral vascular accidents in patients over the age of 60, II; prognosis.","volume":"2","author":"Rankin","year":"1957","journal-title":"Scott Med J"},{"issue":"10","key":"noi190070r22","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/STROKEAHA.115.010049","article-title":"The Heidelberg Bleeding Classification: classification of bleeding events after ischemic stroke and reperfusion therapy.","volume":"46","author":"von Kummer","year":"2015","journal-title":"Stroke"},{"issue":"6","key":"noi190070r23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/1747493017700663","article-title":"Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials.","volume":"12","author":"Ntaios","year":"2017","journal-title":"Int J Stroke"},{"issue":"2","key":"noi190070r24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1538-7836.2007.02848.x","article-title":"Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants.","volume":"6","author":"B\u00fcller","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"11","key":"noi190070r25","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1111\/j.1538-7836.2011.04507.x","article-title":"External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?","volume":"9","author":"Beyer-Westendorf","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"1","key":"noi190070r26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000215942","article-title":"Risk score to predict the outcome of patients with cerebral vein and dural sinus thrombosis.","volume":"28","author":"Ferro","year":"2009","journal-title":"Cerebrovasc Dis"},{"key":"noi190070r21","unstructured":"European Agency for the Evaluation of Medicinal Products. Note for guidance on clinical investigation of medicinal products for the treatment of venous thromboembolic disease. Committee for Proprietary Medicinal Products. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/note-guidance-clinical-investigation-medicinal-products-treatment-venous-thromboembolic-disease_en.pdf. Published December 16, 1999. Accessed October 17, 2018."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2749167\/jamaneurology_ferro_2019_oi_190070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T16:00:59Z","timestamp":1575907259000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2749167"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.2764","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}